RepliCel Life Sciences Inc.

RP:TSX.V; REPCF:OTCQB

Last:
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

RepliCel Life Sciences Inc. is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The Companyís product pipeline is comprised of two ongoing clinical trials (RCT-01: tendon repair and RCS-01: skin rejuvenation) as well as its RCH-01: hair restoration product under exclusive license by Shiseido Company for certain Asian countries. All product candidates are based on RepliCelís innovative technology, utilizing cell populations isolated from a patientís healthy hair follicles. The Company has also developed a proprietary injection device (RCI-02) optimized for the administration of its products and licensable for use with other dermatology applications.